Akums Drugs & Pharmaceuticals Limited – India’s Leading CDMO & Pharmaceutical Manufacturer
Akums Drugs & Pharmaceuticals Limited, headquartered in Delhi, India, is the country’s largest contract development and manufacturing organization (CDMO), specializing in pharmaceutical formulations, active pharmaceutical ingredients (APIs), and branded generic medicines. With cutting-edge manufacturing facilities, regulatory compliance, and innovation-driven R&D, Akums has positioned itself as a global leader in pharmaceutical contract manufacturing.
Core Business & Specialization
Akums Drugs & Pharmaceuticals is a fully integrated CDMO, offering end-to-end pharmaceutical manufacturing solutions, including:
- Formulation development
- API manufacturing
- Branded generics production
- Regulatory support
- Technology transfer & licensing
- Quality assurance and compliance
The company caters to leading pharmaceutical brands worldwide, providing customized drug formulations and private-label manufacturing.
Product Portfolio
1. Pharmaceutical Formulations
Akums manufactures over 12,000+ drug formulations, covering various dosage forms, including:
- Tablets – Immediate release, controlled release, chewable, and effervescent tablets.
- Capsules – Hard gelatin and enteric-coated capsules.
- Soft Gelatin Capsules – Nutraceutical and pharmaceutical-grade soft gels.
- Liquid Orals – Syrups, suspensions, and solutions.
- Sachets – Single-dose granule formulations.
- Vials & Ampoules – Injectable medications in sterile packaging.
- Topical Preparations – Creams, ointments, gels, and lotions.
- Eye Drops – Sterile ophthalmic solutions.
- Dry Powder Injections – High-potency parenteral formulations.
- Rotacaps & DPI – Dry powder inhalation therapies.
- Gummies – Nutraceutical soft-chew formulations.
2. Active Pharmaceutical Ingredients (APIs)
Akums produces a diverse range of high-quality APIs, catering to key therapeutic segments, including:
- Cardiovascular diseases
- Diabetes management
- Pain management
- Anti-infectives
- Gastrointestinal disorders
- Neurological and psychiatric treatments
- Respiratory therapies
- Dermatological solutions
- Vitamins, minerals, and nutraceuticals
3. Branded Formulations
Akums manufactures branded generic medicines under its Evalife brand, as well as custom-labeled pharmaceutical products for major pharma companies.
Manufacturing Capabilities & Facilities
Akums operates 15+ state-of-the-art WHO-GMP, USFDA, and EU-GMP compliant manufacturing facilities across India, with:
- Annual production capacity of 20 billion tablets, 10 billion capsules, 2 billion ampoules, and 1 billion soft gels.
- Largest soft gelatin manufacturing capacity in India.
- Fully automated aseptic manufacturing units for sterile formulations.
- Dedicated R&D centers for formulation innovation and process development.
- Advanced packaging technology for tamper-proof and high-shelf-life pharmaceutical products.
Regulatory Approvals & Quality Certifications
Akums ensures strict adherence to global regulatory standards, making its products compliant with:
- WHO-GMP Certification – Ensuring high-quality manufacturing practices.
- USFDA & EU-GMP Approvals – Authorized for exports to the United States and European Union.
- TGA (Australia), ANVISA (Brazil), and Health Canada Approvals – Meeting international regulatory guidelines.
- ISO 9001:2015 Certified – Quality management system compliance.
- FSSAI Approved – Regulatory compliance for nutraceutical and food-grade formulations.
Global Market Presence & Strategic Partnerships
Akums serves more than 1,500 pharmaceutical companies across 50+ countries, including:
- India
- United States
- Europe
- Latin America
- Middle East & Africa
- Southeast Asia
The company has long-term partnerships with leading multinational pharmaceutical companies and has contributed to the launch of multiple blockbuster generic and nutraceutical products globally.
Financial Growth & Business Performance
Akums has shown strong financial growth and expansion, driven by contract manufacturing demand and API exports.
- Annual revenue exceeding $1.2 billion.
- 15-20% year-on-year growth in contract manufacturing operations.
- Investment in new biologics and biosimilars manufacturing capabilities.
- Expansion into complex generics and oncology drug formulations.
Industry Recognition & Competitive Edge
Akums has received multiple awards for its excellence in pharmaceutical manufacturing and R&D innovation.
- “Best Contract Manufacturing Organization” at CPhI Awards.
- Recognized as India's largest third-party pharmaceutical manufacturer.
- Winner of multiple “Excellence in Quality” awards by pharma industry associations.
- Patented and proprietary drug delivery innovations in sustained release and fast-acting formulations.
Future Growth & Expansion Plans
Akums is investing heavily in biopharmaceuticals, high-potency drugs, and novel drug delivery technologies. Key focus areas for expansion include:
- Expansion into oncology, biosimilars, and personalized medicine.
- Increased production capacity for sterile injectables and biologics.
- Acquisition of advanced R&D capabilities for new drug formulations.
- Strengthening global distribution channels and exports.
Conclusion
With its strong commitment to quality, innovation, and regulatory compliance, Akums Drugs & Pharmaceuticals Limited is a leading force in the global pharmaceutical manufacturing industry. The company’s state-of-the-art facilities, diverse product portfolio, and strategic partnerships position it as a trusted CDMO for major pharmaceutical brands worldwide.
